Brief: Ascentage Pharma Group International Says Unit's Drug Candidate Olverembatinib Approved By NMPA
25/11/2021 14:06
Nov 25 (Reuters) - Ascentage Pharma Group International
6855.HK :
* CLASS I DRUG CANDIDATE OLVEREMBATINIB OF UNIT APPROVED BY
NMPA
Further company coverage: 6855.HK
(Reuters.Briefs@thomsonreuters.com)
Recent news on Ascentage Pharma International
See all newsBrief: Ascentage Pharma Group Says Lisaftoclax Granted Breakthrough Therapy Designation In China
China's Ascentage Pharma climbs as chairman buys shares on market
Brief: Ascentage Pharma Group International's Chairman Buys 38,630 Shares
Brief: Ascentage Pharma Group International Posts H1 Net Loss Attributable RMB816.7 Million
China's Ascentage Pharma H1 revenue rises 29% on Lisaftoclax ramp-up